The global blood platelets market is anticipated to register considerable gains through 2030. The industry expansion can be credited to the growing demand for platelet transfusions due to the rising cases of hemophilia. The constantly evolving patient safety standards have bolstered the realization for blood therapies that entail fewer complications, which shapes the industry outlook.

To that end, blood banks and healthcare units are increasingly investing in medical advancements to bring safe transfusion systems to their portfolio of services. The presence of government agencies that regulate blood and blood component collection is also shaping the industry scenario.

The high treatment costs associated with blood platelet therapies and awareness around the risk of infection are likely to hold back market revenues. The high associated costs make the treatment inaccessible to patients belonging to low socioeconomic background and low-income countries, which greatly limits the industry scope.

The overall blood platelets market landscape is bifurcated into segments such as platelet, application, end-use, and regional outlook.

Based on platelet, the market is segmented into whole blood derived platelets and apheresis derived platelets. Amongst them, whole blood derived platelets segment is witnessing surging demand owing to the crucial role they play in organ transplant and oncological procedures. WBD platelets are typically derived from four to five whole blood donations and are increasingly used in standard transfusion procedures. The collected platelets are frequently leukoreduced, pooled, and bacterially tested, which increases their usage in healthcare settings.

On the basis of application, the industry is divided into thrombocytopenia, hemophilia, platelet function disorders, perioperative Indications, and hemato-oncology. The market is projected to experience an elevated demand from the platelet function disorders segment, driven by the increasing prevalence of platelet disorders. The bleeding disorders accompanied by such defects increase the need for blood platelets to lessen the severity of the ailments.

Based on end use, the industry is categorized into hospitals and ambulatory centers. The hospital segment is set to gain considerable traction over 2022-2030, owing to increasing advancements in blood, collection, transfusion, and blood-related therapies. The higher level of expertise with respect to donor screening, data automation, and improved transfusion practices, sways patient inclination towards the hospital settings, fostering segment growth. The presence of highly trained staff also works in favor of the segment.

From a regional viewpoint, the market is segmented into North America, the Middle East and Africa, Latin America, Asia Pacific, and Europe. The Asia Pacific segment valuation is poised to surpass USD 1.5 billion owing to the rising presence of blood banks in the region. Their expansion is being driven by increasing investments towards the strengthening of healthcare infrastructure. Additionally, the emergence of NGO sector blood banks in countries like India, Bangladesh, and Pakistan is also anticipated to augment the industry expansion.